Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

Table 2 Univariate and multivariate Cox analysis (n = 52)

Variable	PFS (months)	Univariate analysis		Multivariate analysis
Variable	PFS (months)	HR (95% CI)	P value	HR (95% CI)	P value
Age (years) ≥ 65 vs. < 65	22.57 vs. 9.57	0.47 (0.26–0.84)	0.009	0.18 (0.06–0.51)	0.001
PFS of 1^st-G EGFR-TKI ≥ 12 vs. < 12 months	10.70 vs. 8.17	0.44 (0.27–0.72)	0.0008	0.67 (0.28–1.62)	0.379
*TP53* Mut. vs. WT	9.87 vs. 14.30	1.62 (0.85–3.10)	0.119	0.55 (0.21–1.41)	0.213
*PARP1* Mut. vs. WT	3.77 vs. 13.70	8.40 (2.15–32.80)	0.0003	11.39 (2.45–52.82)	0.002
*MYC* Amp vs. WT	4.83 vs. 12.60	2.95 (1.17–7.43)	0.016	1.19 (0.42–3.40)	0.744
TMB (Mut./Mb) TMB-H vs. TMB-L	6.77 vs. 19.10	3.6 (1.71–7.58)	0.0004	6.65 (2.59–17.04)	8.00E-05

HR Hazard ratio, WT Wild-type, Amp Amplification, Mut Mutation, PFS Progression-free survival

ISSN: 1471-2407